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signiﬁcant improvements in glycemic control (HbA1c 0.59%)
and body weight (BMI 0.52 kg.m-2). The aim of this analysis
was to estimate the long-term clinical and cost implications asso-
ciated with therapy conversion from insulin glargine to detemir
in type 2 diabetes patients in Germany. METHODS: A previ-
ously published and validated diabetes model (CORE Diabetes
Model) was used to make long-term projections of clinical and
cost outcomes based on patient characteristics (age 62.3 years,
duration of diabetes 7 years, HbA1c 8.30%, 50.4% male) and
treatment effects from the German part of PREDICTIVE. The
model was used to estimate life-expectancy, quality-adjusted life
expectancy and to account direct medical costs (pharmacy,
patient management and complication costs). Costs were derived
from published sources and expressed in 2006 Euros. Future
costs and clinical beneﬁts were discounted at 5% annually.
RESULTS: Therapy conversion from insulin glargine to insulin
detemir was projected to improve life expectancy by approxi-
mately 0.13 years (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.29 quality-adjusted life
years (QALYs) (4.53  0.09 versus 4.24  0.08 QALYs). Direct
costs associated with insulin detemir treatment were projected
to be lower over patient lifetimes than with glargine (€
54,807  1,788 versus € 55,839  1,749 per patient, difference
€ 1,032). Cost savings were driven by lower complication costs
(due to HbA1c improvements) associated with insulin detemir.
CONCLUSION: Modeling the long-term implications of therapy
conversion from insulin glargine to detemir based on data from
German patients in PREDICTIVE indicates that insulin detemir
is associated with beneﬁts in terms of life expectancy, quality-
adjusted life expectancy and complication rates, as well as reduc-
ing costs from a third-party health care payer perspective in
Germany.
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OBJECTIVES: To assess the costs and effects of Januvia versus
Avandia as supplementary treatment in combination with met-
formin, for patients with type 2 diabetes in whom metformin (in
addition to diet and exercise) does not provide adequate glycemic
control. METHODS: The Disease Elimination Life Table Analy-
sis (DELTA) cohort model was used to assess the costs and effects
of Januvia (100 mg) in comparison to Avandia (8 mg). The
model contains ﬁve sub models representing diabetes related
complications. Estimates of disease progression, incidence in the
sub models, disease related mortality, and all cause mortality,
were derived from the UK Prospective Diabetes Study. Estimates
regarding drug efﬁcacy and adverse events were based on an
18-week head-to-head comparison of Januvia 100 mg versus
Avandia 8 mg supplementary to metformin. The analysis was
conducted from a societal perspective. Direct and indirect costs
were included. Effects were reported as (disease-free) life years
and quality-adjusted life years (QALY). To determine the robust-
ness of the model and the impact of uncertainty, uni- and mul-
tivariate sensitivity analyses were carried out. RESULTS: Januvia
is estimated to be the dominant treatment when compared to
Avandia 8 mg. The univariate sensitivity analyses revealed this
conclusion to be robust over a wide range of values. Results from
the multivariate sensitivity analysis estimate the probability that
Januvia combines additional effectiveness with cost savings at
59%, the probability that Januvia gains QALYs at additional
costs at 13%. The probability that Januvia is less effective is
estimated at 28% (15% with cost savings and in 13% with
additional costs). CONCLUSION: Conditional on the correct-
ness of the estimates and assumptions made, Januvia 100 mg is
dominant over 8 mg Avandia. Sensitivity analyses suggest results
are robust to reasonable changes in input parameters.
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OBJECTIVES: The aim of this analysis was to project the long-
term clinical and economic outcomes associated with therapy
conversion to insulin detemir from Neutral Protamine Hagedorn
(NPH) insulin in patients with type 2 diabetes in the German
setting. METHODS: A previously published and validated com-
puter simulation model of diabetes was used to make long-term
projections of clinical and cost outcomes based on patient char-
acteristics and treatment effects from a sub-analysis of the PRE-
DICTIVE study. Data from PREDICTIVE indicated that therapy
conversion from NPH insulin to insulin detemir was associated
with signiﬁcant improvements in glycemic control (HbA1c
-0.6%) and reduced weight gain (body mass index -0.382 kg/
m2). Based on these clinical ﬁndings, the computer simulation
model was used to estimate life-expectancy, quality-adjusted life
expectancy and costs from a third party healthcare payer per-
spective. Future costs and clinical beneﬁts were discounted at 5%
per annum. RESULTS: Conversion to insulin detemir was pro-
jected to improve life expectancy by approximately 0.13 years
compared to NPH (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.28 quality-adjusted life
years (QALYs) (4.51  0.09 versus 4.23  0.08 QALYs). Direct
medical costs over patient lifetimes were projected to be margin-
ally lower in patients receiving insulin detemir compared to NPH
(€ 54,575  1,842 versus € 54,640  1,739, difference € 65 per
patient). Pharmacy costs were higher with insulin detemir
(€ 14,129 versus € 12,230, difference € 1,899) but were more
than offset by cost savings due to complications avoided (com-
plication costs € 38,246 versus € 40,242, difference € 1,996).
CONCLUSIONS: This modeling study, based on a German sub-
analysis of PREDICTIVE, suggests that therapy conversion from
NPH to insulin detemir is likely to be associated with long-term
clinical beneﬁts and may well be cost saving in type 2 diabetes
patients in the German setting.
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OBJECTIVES: Based on the clinical results of the LAPTOP trial,
a cost analysis from the perspective of the German Statutory
Health Insurance (SHI) was performed. In addition a model
simulation of the long term complications was conducted using
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the Diabetes-Mellitus-Model (DMM version 3.2). METHODS:
Cost analysis: Costs during the ﬁrst year of treatment after
switching to either BOT (glargine plus glimepirid and metform-
ine) or CT (premixed insulin 30/70) were analysed. Costs for
antidiabetic agents, injection devices (pens, syringes) and moni-
toring devices (test strips, lancets) were included. Other medical
supplies were assumed to be the same or not relevant from the
SHI perspective. Insulin utilization was extrapolated up to one
year by linear regression based on LAPTOP trial data. The cost
of drugs, devices and supplies (retail prices) were taken from
ofﬁcial standard sources. Univariate sensitivity analyses were
performed for all cost parameters (variation 20%). DMM-
Simulation: Baseline values for the model simulation were as
follows: mean age of the population 60  9.0 years, mean dura-
tion of diabetes 9.0  7.0 years and mean HbA1c value
8.8  0.9%. The response rate (HbA1c  7%) for BOT was
49% and for CT 39%. Mean HbA1c values for responders were
6.46% and 6.55% respectively. RESULTS: Annual savings with
the BOT regimen add up to 236.35€. Insulin utilization and
insulin prices had the highest impact on overall costs. The rela-
tive risk reduction (RRR) for micro-vascular events after 10
simulation years varied between 14% (end stage renal disease)
and 2% (retinopathy) in favour of BOT versus CT. CONCLU-
SION: The combined results of these two analyses show that
BOT in addition to its short (HbA1c) and long term (micro-
vascular events) medical beneﬁts is associated with lower costs
from the SHI perspective.
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OBJECTIVES: To compare CVD event-related costs among
patients with Type 2 diabetes (T2D) with and without insulin
use. METHODS: Patients with T2D were identiﬁed from insur-
ance claims (1998–2004) of a large US health insurance plan.
Index date was date of ﬁrst CVD event; for subjects without
CVD events, index date was a medical claim date in the same
calendar quarter as the index date for a matched subject in the
CVD group. Baseline period was a minimum of 12 months prior
to index date, with variable follow-up after index date. Filled
prescriptions for insulin were identiﬁed from pharmacy claims.
US Census data were used to identify distributions of ethnicity
and income. Patients with and without insulin use were com-
pared on inﬂation-adjusted CVD-event related medical costs,
adjusted for other risk factors. Two-part models were estimated;
the ﬁrst part used logistic regression to estimate probability of
any cost. The second part estimated mean cost among patients
with costs >$0; results were compared for estimations using
GLM vs. OLS on a log-transformed cost with heteroskedastic
smearing estimator. RESULTS: Among 342,638 T2D patients,
4.3% used insulin. Average CVD event-related medical costs
were $646 and $705 in insulin vs. non-insulin users (p = 0.5590).
Among non-insulin users, 6.0% incurred costs, vs. 4.8% of
patients with insulin use (p < 0.0001). Adjusted odds of incurring
CVD event related costs were 25% lower for insulin-users than
for non-insulin users (OR = 0.75, 95% CI: 0.68, 0.82). Among
patients with costs, adjusted mean costs were not statistically
signiﬁcantly different between insulin and non-insulin groups,
regardless of estimation technique. CONCLUSION: T2D
patients with history of insulin use were less likely to incur
CVD-related medical costs than non-insulin users, despite adjust-
ment for risk factors. However, average costs were not statisti-
cally signiﬁcantly different between groups. Estimation technique
had a substantial impact on range of predicted mean costs.
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OBJECTIVES: Modern insulin analogues such as insulin aspart
(IAsp, NovoRapid) offer beneﬁts in terms of glycemic control,
improved hypoglycemic proﬁle and faster onset of action com-
pared to human insulin (HI). A modeling analysis was performed
to estimate the long-term economic savings due to reduced com-
plications in Polish type 2 diabetes patients switching to meal-
time IAsp from HI basal-bolus therapy, based on results of the
European PREDICTIVE study. METHODS: Treatment effects
(changes in HbA1c, hypoglycemic event rate and body weight)
were derived from PREDICTIVE. Baseline cohort characteristics
were taken from published data representative of Polish type 2
diabetes patients and supplemented with trial data. A published
and validated diabetes model was used to project long-term
outcomes and account costs for patients receiving either meal-
time IAsp or HI as part of a basal-bolus therapy, with or without
oral antidiabetic agents. Costs were derived from published
sources and accounted from a health care payer perspective in
2006 Polish Zlotych (PLN). Future economic and clinical out-
comes were discounted at 5% annually. RESULTS: Projections
indicated that IAsp was associated with improvements in life
expectancy of 0.03 years compared to HI (5.12  0.12 versus
5.09  0.12 years). Improved glycemic control with IAsp led to
reduced incidence of renal complications, resulting in a mean
cost saving of approximately PLN 360 per patient (PLN 2910
versus 3270). Mean cardiovascular complication costs were
comparable with both treatments (PLN 5697 versus 5769 per
patient) due mainly to a high baseline prevalence in the cohort.
Small cost savings were observed in terms of eye, diabetic foot
and other complications over patient lifetimes. CONCLUSION:
Improvements in HbA1c and body weight associated with IAsp
(compared to HI) in PREDICTIVE were projected to lead to
long-term cost savings of approximately PLN 480 per patient
(PLN 13,423 versus 13,903) due to complications avoided in
Polish type 2 diabetes patients.
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OBJECTIVES: To determine the cost of illness of type 2 diabetes
mellitus in Colombia from the Ministry of Health and societal
perspectives. METHODS: A previously published Markov tran-
sition model was adapted, using the clinical expertise of a
Colombian endocrinologist. Transition probabilities for the
model were derived from a review of the international literature
on the epidemiology of type 2 diabetes mellitus. Direct resources
were identiﬁed and costed using national pricing lists, interna-
tional health care guidelines, and other Colombian studies, as
well as other costs from different countries. Indirect costs were
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